Oxis Biotech Inc. Scientific Advisory Board Member, Dr. James J. Mule, Named as a Master of Immunology by the American Association for Cancer Research

Aug 11, 2015, 08:30 ET from Oxis International, Inc.

TAMPA, Fla., Aug. 11, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS], is pleased to announce that Dr. James J. Mule, member of the Company's Scientific Advisory Board and Associate Center Director for Translational Science at the Moffitt Cancer Center, has been named a Master of Immunology by the American Association for Cancer Research (AACR) publication.

The distinction recognizes Dr. Mule's contributions to cancer research; in particular, his work to better understand how anti-tumor immune responses develop and are regulated by the body. The results of his life's work have helped shape the future of cancer therapy through the development of personalized immunotherapies that use a patient's own immune system to fight his or her disease.

AACR introduced the Masters of Immunology as a way to recognize and invite leading investigators to present a board overview of the maturation of an important principal in cancer immunology. The cover story of the publication's August issue, co-authored by Mule and Martin C. Mihm, M.D. of Dana-Farber/Harvard Cancer Center, will highlight the historical aspect of tumor-infiltrating lymphocytes in melanoma and immune response.

"The importance of T-cells in cancer has long been recognized, but we now have a better understanding of how tumor-infiltrating lymphocytes (TILs) can affect tumor control and prognosis in patients with melanoma," said Mule. "We are using this knowledge to pinpoint immune-checkpoints and effectively block negative regulators of the anti-tumor immune response for therapeutic benefit."

Oxis CEO Tony Cataldo stated, "I was lucky enough to have Dr. Mule on my SAB when I formed Genesis BioPharma (now Lion Biotechnologies, Inc.). His expertise and guidance in helping companies mature through the rigors of the FDA is invaluable to helping us advance our Multiple Myeloma Therapy."

About Dr. James J. Mule

Dr. James J. Mule, Ph.D. currently serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. Previously, he was in Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He then moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Program at the University of Michigan Comprehensive Cancer Center.

Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI's Board of Scientific and Clinical Counselors. He served as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, and is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

About Oxis Biotech Inc.

OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world's leading cannabinoid researchers and institutions to advance its technologies.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Oxis International
Investor Relations
800-304-9888

 

SOURCE Oxis International, Inc.